Quarterly ResultMay 6, 2026, 07:03 AM
TScan Therapeutics Plans Phase 3 TSC-101 Study; Q1 Net Loss $28.7M
AI Summary
TScan Therapeutics reported a Q1 2026 net loss of $28.7 million, an improvement from $34.1 million in Q1 2025, with revenue decreasing to $1.0 million. The company announced significant pipeline advancements, including the planned initiation of a Phase 3 study for TSC-101 in Q2 2026 and a Phase 1 study for TSC-102-A01 and TSC-102-A03 in H2 2026. TScan also expects to share early data from Cohort C of the ALLOHA Phase 1 trial in Q2 2026 and updated data in H2 2026. The company's cash and cash equivalents of $128.1 million are expected to fund operations into H2 2027.
Key Highlights
- Planned initiation of Phase 3 study for TSC-101 in Q2 2026.
- Early data from Cohort C of ALLOHA Phase 1 trial expected in Q2 2026.
- Initiation of Phase 1 study for TSC-102-A01 and TSC-102-A03 in H2 2026.
- Q1 2026 revenue was $1.0 million, down from $2.2 million in Q1 2025.
- Q1 2026 R&D expenses decreased to $21.9 million from $29.8 million YoY.
- Q1 2026 net loss was $28.7 million, improved from $34.1 million YoY.
- Cash and cash equivalents of $128.1 million fund operations into H2 2027.
- Pro forma outstanding shares were 129,913,077 as of March 31, 2026.